Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. Vol. 61, CA: A Cancer Journal for Clinicians. 2011. p. 69–90.
2.
Kwon KJ, Shim KN, Song EM, Choi JY, Kim SE, Jung HK, et al. Clinicopathological characteristics and prognosis of signet ring cell carcinoma of the stomach. Vol. 17, Gastric Cancer. 2014. p. 43–53.
3.
Ma SH, Jung W, Weiderpass E, Jang J, Hwang Y, Ahn C, et al. Impact of alcohol drinking on gastric cancer development according to Helicobacter pylori infection status. Vol. 113, British Journal of Cancer. 2015. p. 1381–8.
4.
Taghavi S, Jayarajan SN, Davey A, Willis AI. Prognostic Significance of Signet Ring Gastric Cancer. Vol. 30, Journal of Clinical Oncology. 2012. p. 3493–8.
5.
Kranjčević K. Karcinom želuca u praksi liječnika obiteljske medicine. Vol. 69. 2015. p. 333–8.
6.
Lin Y, Ness-Jensen E, Hveem K, Lagergren J, Lu Y. Metabolic syndrome and esophageal and gastric cancer. Vol. 26, Cancer Causes & Control. 2015. p. 1825–34.
7.
Lagergren J, Andersson G, Talbäck M, Drefahl S, Bihagen E, Härkönen J, et al. Marital status, education, and income in relation to the risk of esophageal and gastric cancer by histological type and site. Vol. 122, Cancer. 2016. p. 207–12.
8.
Lauwers GY, Carneiro F, Graham DY, Cuardo MP, Franceschi S, Montgomery E, et al. Gastric carcinoma In: WHO Classification of Tumors of the Digestive System Bosman FT. In 2010.
9.
van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germlineCDH1mutation carriers. Vol. 52, Journal of Medical Genetics. 2015. p. 361–74.
10.
Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary Diffuse Gastric Cancer Syndrome. Vol. 1, JAMA Oncology. 2015. p. 23.
11.
Rubin GP, Saunders CL, Abel GA, McPhail S, Lyratzopoulos G, Neal RD. Impact of investigations in general practice on timeliness of referral for patients subsequently diagnosed with cancer: analysis of national primary care audit data. Vol. 112, British Journal of Cancer. 2015. p. 676–87.
12.
Chiu PWY, Teoh AYB, To KF, Wong SKH, Liu SYW, Lam CCH, et al. Endoscopic submucosal dissection (ESD) compared with gastrectomy for treatment of early gastric neoplasia: a retrospective cohort study. Vol. 26, Surgical Endoscopy. 2012. p. 3584–91.
13.
Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F, et al. Is Preoperative Chemotherapy Followed by Surgery the Appropriate Treatment for Signet Ring Cell Containing Adenocarcinomas of the Esophagogastric Junction and Stomach? Vol. 21, Annals of Surgical Oncology. 2014. p. 1739–48.
14.
Tong J hua, Sun Z, Wang Z ning, Zhao Y hui, Huang B jun, Li K, et al. Early gastric cancer with signet-ring cell histologic type: Risk factors of lymph node metastasis and indications of endoscopic surgery. Vol. 149, Surgery. 2011. p. 356–63.
15.
Sun W, Han X, Wu S, Yang C. Endoscopic Resection Versus Surgical Resection for Early Gastric Cancer. Vol. 94, Medicine. 2015. p. e1649.
16.
Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Vol. 254. 2011. p. 684–93.
17.
ŽMaksimović. Hirurgija-udžbenik za studente. Medicinski fakultetet Univerziteta u Beogradu. Treće izmenjeno i dopunjeno izdanje.
18.
Pernot S. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. Vol. 21, World Journal of Gastroenterology. 2015. p. 11428.
19.
Andric Z, Randjelovic T, Kovcin V, Gutovic J, Crevar S, Murtezani Z, et al. Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer. Vol. 140, Srpski arhiv za celokupno lekarstvo. 2012. p. 305–12.
20.
NAMIKAWA T, MUNEKAGE E, MUNEKAGE M, MAEDA H, YATABE T, KITAGAWA H, et al. Evaluation of a trastuzumab-containing treatment regimen for patients with unresectable advanced or recurrent gastric cancer. Vol. 5, Molecular and Clinical Oncology. 2016. p. 74–8.
21.
Abnet CC, Corley DA, Freedman ND, Kamangar F. Diet and Upper Gastrointestinal Malignancies. Vol. 148, Gastroenterology. 2015. p. 1234-1243.e4.
22.
Nelson N. On Trial: Evidence From Using Aspirin to Prevent Cancer: Vol. 107, Journal of the National Cancer Institute. 2015. p. djv265.
23.
Wise J. EradicatingH pyloriseems to reduce incidence of gastric cancer, review shows: BMJ. p. h3963.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.